| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.6 |